Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Enric Carcereny et al.|The Lancet Oncology|2012Cited by 5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerRafael Rosell, Miquel Tarón, Teresa Morán et al.|New England Journal of Medicine|2009Cited by 2.4k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisJustin F. Gainor, Mari Mino–Kenudson, Ryan J. Sullivan et al.|Clinical Cancer Research|2016Cited by 1.2k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerHiroyuki Yasuda, Daniel B. Costa, Eunyoung Park et al.|Science Translational Medicine|2013Cited by 565
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patientsH. Cortés-Funes, Miquel Tarón, Carlos Gegúndez Gómez et al.|Annals of Oncology|2005Cited by 231